Big Tech's Growth Faces Challenges
This is a Skyrizi news story, published by Yahoo Finance, that relates primarily to Benzinga news.
Skyrizi news
For more Skyrizi news, you can click here:
more Skyrizi newsBenzinga news
For more Benzinga news, you can click here:
more Benzinga newstech giants news
For more tech giants news, you can click here:
more tech giants newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best tech news, business news, entertainment news, and much more. If you like tech giants news, you might also like this article about
Biotech stocks. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest momentum Big Tech news, Big Tech news, tech giants news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
biotech sharesBenzinga
•Here are 3 biotech stocks that could replace the Magnificent Seven in 2025: Merck, Bristol Myers Squibb and AbbVie
71% Informative
Big Tech's runaway growth created gains, but headwinds are forming and some observers doubt the Mag Seven can sustain its momentum in 2025 .
Merck ( NYSE MRK) Merck is one of the world's best-known suppliers of vaccines, medical treatments and veterinary products.
Bristol Myers Squibb ( NYSE : BMY ) is another well-respected biotech company specializing in medicines fighting serious diseases.
AbbVie produces some of the world's most recognizable autoimmune disorder medications in Skyrizi and Rinvoq .
The company is also a Dividend King and pays a respectable 3.74% per share.
Benzinga 's survey of 36 analysts shows a consensus price target of $ 192.13 .
VR Score
68
Informative language
70
Neutral language
15
Article tone
formal
Language
English
Language complexity
38
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
15
Affiliate links
no affiliate links